Silo pharma files patent for groundbreaking ketamine implant therapeutic to target fibromyalgia and chronic pain

Silo reports positive stability of sp-26 for time-release and dosage control sarasota, fl, march 18, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘methods and combinations for managing pain' with the united states patent and trademark office (uspto). the patent application includes protection for the company's sp-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
SILO Ratings Summary
SILO Quant Ranking